25 completed, 4 active not recruiting, 2 terminated, 2 withdrawn. 20 Phase 2, 16 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow reolysin: new trials by email Literature Review of reolysin trials Research Report on reolysin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Bevacizumab, FOLFIRI, Pelareorep - Ras-mutated Metastatic Colorectal Cancer, mCRC | Phase 2 | Recruiting | Oncolytics Biotech | 60 | 2026-04-30 | 2026-10-27 |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 10 | 2022-10-07 | 2026-05-13 |
| A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel - Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified | Phase 1 / Phase 2 | Active not recruiting | Oncolytics Biotech | 122 | 2021-10-27 | 2026-05-19 |
| Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer Pelareorep - Advanced or Metastatic Breast Cancer | Phase 1 | Completed | Adlai Nortye Biopharma Co., Ltd. | 15 | 2021-10-11 | 2023-11-22 |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study Pelareorep, Quality-of-Life Assessment, Questionnaire Administration - Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma | Phase 2 | Active not recruiting | Mridula George, MD | 25 | 2020-07-13 | 2025-04-04 |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Paclitaxel, Pelareorep, Avelumab - Breast Cancer Metastatic | Phase 2 | Active not recruiting | Oncolytics Biotech | 48 | 2020-06-10 | 2025-01-16 |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer Pelareorep, Letrozole, Atezolizumab - Breast Cancer | Early Phase 1 | Terminated | Oncolytics Biotech | 26 | 2019-03-29 | 2022-08-15 |
| Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Pembrolizumab, Wild-type Reovirus - Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 2 | Terminated | Northwestern University | 17 | 2018-11-14 | 2022-10-05 |
| Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma Carfilzomib, Dexamethasone, Nivolumab - Recurrent Plasma Cell Myeloma | Phase 1 | Completed | Emory University | 23 | 2018-10-24 | 2023-10-06 |
| REO13 Melanoma With of Without GM-CSF Reolysin, GM-CSF - Melanoma, Cancer of Skin | Phase 1 / Phase 2 | Withdrawn | University of Leeds | 2017-10-01 | 2018-05-04 | |
| Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma Lenalidomide or Pomalidomide, REOLYSIN - Multiple Myeloma | Phase 1 | Unknown | University of Leeds | 4 | 2017-06-05 | 2020-01-22 |
| Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder REOLYSIN®, Gemcitabine, Cisplatin - Muscle-invasive Transitional Cell Carcinoma of the Bladder | Phase 1 | Withdrawn | Oncolytics Biotech | 2017-02-28 | 2017-03-07 | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma REOLYSIN®, Chemotherapy, Gemcitabine - Pancreatic Adenocarcinoma | Phase 1 | Completed | Oncolytics Biotech | 11 | 2015-12-01 | 2018-09-13 |
| Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Completed | University of Southern California | 14 | 2015-08-21 | 2023-08-14 |
| Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus - Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Completed | Mayo Clinic | 6 | 2015-06-21 | 2023-04-24 |
| Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis - Anemia, Recurrent Multiple Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2014-12-09 | 2024-05-17 |
| A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Paclitaxel, Reolysin - Metastatic Breast Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 81 | 2013-02-20 | 2023-08-04 |
| Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer Docetaxel, Reolysin and Prednisone, Docetaxel and Prednisone - Prostate Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 85 | 2012-12-14 | 2023-08-04 |
| Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin - Non Small Cell Lung Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 166 | 2012-12-10 | 2023-08-04 |
| Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer Folfox plus Bevacizumab and reolysin, Folfox plus Bevacizumab - Colorectal Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 109 | 2012-10-26 | 2023-08-23 |
Showing 20 of 35. Sign in to see all of them.
Multiple Myeloma (6) · Breast Neoplasms (4) · Carcinoma (4) · Neoplasm Metastasis (4) · Melanoma (3) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Fallopian Tube Neoplasms (2) · Glioma (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Anemia (1)
Oncolytics Biotech (15) · National Cancer Institute (NCI) (7) · Canadian Cancer Trials Group (4) · University of Leeds (2) · University of Southern California (2) · Adlai Nortye Biopharma Co., Ltd. (1) · Emory University (1) · Mayo Clinic (1) · Mridula George, MD (1) · Northwestern University (1)
United States (25) · Canada (6) · Germany (2) · Spain (2) · United Kingdom (2) · Belgium (1) · China (1) · France (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Russia (1) · Slovenia (1)
Alain Mita, MD (1) · Anne Noonan (1) · Bernhard Eigl (1) · Craig C Hofmeister (1) · Craig Hofmeister (1) · Craig Hofmeister, MD, MPH (1) · David Cohn (1) · David E Cohn (1) · Derek Jonker (1) · Devalingam Mahalingam (1) · Devalingam Mahalingam, MD, PhD (1) · Donald G Morris (1) · E. Anders Kolb (1) · Evanthia Galanis (1) · Gordon Cook (1)
PMID 26719427, PMID 27039845, PMID 29027598, PMID 29186319, PMID 29487723, PMID 29653857, PMID 29748010, PMID 37443348, PMID 37812476, PMID 39828738
P30CA016058 (4), U01CA076576 (3), N01CM00070 (2), P30CA014089 (2), N01CM62207 (1), P30CA015083 (1), P30CA060553 (1), P30CA072720 (1), P30CA138292 (1), U01CA097452 (1), U10CA027469 (1), U10CA180868 (1), UM1CA186691 (1), UM1CA186712 (1)